Needham & Company LLC Increases Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $33.00

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target increased by investment analysts at Needham & Company LLC from $30.00 to $33.00 in a research report issued to clients and investors on Wednesday, Marketbeat reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 149.81% from the stock’s current price.

A number of other analysts have also weighed in on DAWN. Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. The Goldman Sachs Group cut their price objective on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. JPMorgan Chase & Co. upped their price objective on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Piper Sandler reissued an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $39.33.

Day One Biopharmaceuticals Stock Down 13.0 %

Shares of NASDAQ DAWN opened at $13.21 on Wednesday. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -5.55 and a beta of -1.48. Day One Biopharmaceuticals has a 52-week low of $9.67 and a 52-week high of $17.85. The business’s 50 day moving average is $15.23 and its two-hundred day moving average is $13.79.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Analysts anticipate that Day One Biopharmaceuticals will post -2.66 EPS for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the transaction, the insider now owns 1,244,662 shares in the company, valued at $18,981,095.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the sale, the insider now owns 1,244,662 shares in the company, valued at $18,981,095.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Charles N. York II sold 2,666 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $40,656.50. Following the sale, the chief financial officer now owns 277,754 shares of the company’s stock, valued at approximately $4,235,748.50. The disclosure for this sale can be found here. Insiders sold 55,781 shares of company stock worth $883,160 over the last 90 days. Corporate insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several hedge funds have recently made changes to their positions in DAWN. SG Americas Securities LLC boosted its stake in shares of Day One Biopharmaceuticals by 58.7% during the third quarter. SG Americas Securities LLC now owns 36,980 shares of the company’s stock worth $454,000 after buying an additional 13,683 shares during the period. Bank of New York Mellon Corp lifted its position in Day One Biopharmaceuticals by 22.4% in the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock valued at $2,703,000 after purchasing an additional 40,387 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Day One Biopharmaceuticals by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 43,567 shares of the company’s stock valued at $535,000 after purchasing an additional 8,522 shares during the period. TD Asset Management Inc lifted its position in Day One Biopharmaceuticals by 100.0% in the third quarter. TD Asset Management Inc now owns 55,196 shares of the company’s stock valued at $677,000 after purchasing an additional 27,598 shares during the period. Finally, Hennion & Walsh Asset Management Inc. lifted its position in Day One Biopharmaceuticals by 89.5% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 53,803 shares of the company’s stock valued at $660,000 after purchasing an additional 25,414 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.